-
公开(公告)号：US20190241966A1
公开(公告)日：2019-08-08
申请号：US16226406
申请日：2018-12-19
Applicant: Rosetta Genomics Ltd.
Inventor： Ranit Aharonov , Nitzan Rosenfeld , Shai Rosenwald
IPC: C12Q1/6886
CPC classification number: C12Q1/6886 , C12Q2600/158 , C12Q2600/178
Abstract: The present invention provides a process for classification of cancers and tissues of origin through the analysis of the expression patterns of specific microRNAs and nucleic acid molecules relating thereto. Classification according to a microRNA tree-based expression framework allows optimization of treatment, and determination of specific therapy.
-
公开(公告)号：US10301627B2
公开(公告)日：2019-05-28
申请号：US15813584
申请日：2017-11-15
Applicant: Regulus Therapeutics Inc. , Rosetta Genomics Ltd.
Inventor： C. Frank Bennett , Ayelet Chajut , Christine Esau , Eric Marcusson , Noga Yerushalmi
IPC: C12N15/113 , A61K31/7105 , A61K31/7088 , A61K45/06 , A61K31/407 , A61K31/44 , A61K31/4745 , A61K31/513 , A61K31/555 , A61K31/704 , A61K31/7048 , A61K31/7068
Abstract: Provided herein are methods for the treatment of liver cancer. These methods encompass the administration of a compound comprising a modified oligonucleotide, wherein the modified oligonucleotide is targeted to a miRNA. Also provided herein are compositions for the treatment of liver cancer. Such compositions include compounds comprising a modified oligonucleotide, wherein the modified oligonucleotide is targeted to a miRNA. Certain miRNAs have been identified as overexpressed in liver cancer, such as, for example, hepatocellular carcinoma, and are thus selected for targeting by modified oligonucleotides. Further, certain miRNAs have been identified as overexpressed in hepatocellular carcinoma cells exposed to dioxin, and are thus selected for targeting by modified oligonucleotides. Antisense inhibition of certain of these miRNAs has been found to inhibit cell proliferation and induce apoptosis.
-
公开(公告)号：US20190112665A1
公开(公告)日：2019-04-18
申请号：US15975533
申请日：2018-05-09
Applicant: ROSETTA GENOMICS LTD. , MOR RESEARCH APPLICATIONS
Inventor： Moshe Hoshen , Gila Lithwick Yanai , Ram Eitan
IPC: C12Q1/6886 , A61K31/713 , A61K45/00
Abstract: Described herein are compositions and methods for the prediction of the prognosis of ovarian cancer subjects. The present invention further provides methods for distinguishing between histological subtypes of ovarian cancer tumors, and also methods and compositions for the treatment or prevention of ovarian cancer. Specifically the invention relates to microRNA molecules associated with said methods and compositions, as well as various nucleic acid molecules relating thereto or derived therefrom.
-
公开(公告)号：US09920379B2
公开(公告)日：2018-03-20
申请号：US15586747
申请日：2017-05-04
Applicant: Rosetta Genomics Ltd.
Inventor： Itzhak Bentwich , Amir Avniel , Yael Karov , Ranit Aharonov
IPC: C12N15/11 , C12Q1/68 , A61K38/00 , C12N15/113
CPC classification number: C12N15/113 , A61K38/00 , C12N15/111 , C12N2310/14 , C12N2310/141 , C12N2310/531 , C12N2320/10 , C12N2320/11 , C12N2320/30 , C12N2330/10 , C12Q1/6809 , C12Q1/6876 , C12Q1/6886 , C12Q2600/106 , C12Q2600/136 , C12Q2600/158 , C12Q2600/16 , C12Q2600/178 , Y02A90/26
Abstract: Described herein are polynucleotides associated with prostate and lung cancer. The polynucleotides are miRNAs and miRNA precursors. Related methods and compositions that can be used for diagnosis, prognosis, and treatment of those medical conditions are disclosed. Also described herein are methods that can be used to identify modulators of prostate and lung cancer.
-
公开(公告)号：US09834821B2
公开(公告)日：2017-12-05
申请号：US14592111
申请日：2015-01-08
Applicant: ROSETTA GENOMICS LTD.
Inventor： Ranit Aharonov , Nitzan Rosenfeld , Hila Benjamin
IPC: C12Q1/68
CPC classification number: C12Q1/6886 , C12Q2600/112 , C12Q2600/158 , C12Q2600/16 , C12Q2600/178
Abstract: The present invention provides nucleic acid sequences that are used for identification, classification and diagnosis of specific types of cancers. The nucleic acid sequences can also be used for prognosis evaluation of a subject based on the expression pattern of a biological sample.
-
Patent Agency Ranking
公开(公告)号：US09624556B2
公开(公告)日：2017-04-18
申请号：US14797381
申请日：2015-07-13
Applicant: Rosetta Genomics Ltd.
Inventor： Itzhak Bentwich , Amir Avniel , Yael Karov , Ranit Aharonov
CPC classification number: C12Q1/701 , C12N15/111 , C12N15/1131 , C12N2310/14 , C12N2310/141 , C12N2320/10 , C12N2320/30 , C12N2330/10 , C12N2710/16222 , C12Q2600/136
Abstract: Described herein are novel polynucleotides associated with viral infections. The polynucleotides are miRNAs and miRNA precursors. Related methods and compositions that can be used for diagnosis, prognosis, and treatment of those medical conditions are disclosed. Also described herein are methods that can be used to identify modulators of viral infections.
-
公开(公告)号：US20170016076A1
公开(公告)日：2017-01-19
申请号：US15237364
申请日：2016-08-15
Applicant: ROSETTA GENOMICS, LTD.
Inventor： Zohar Barnett-Itzhaki , Gila Lithwick Yanai , Eti Meiri , Yael Spector , Hila Benjamin , Nir Dromi
CPC classification number: C12Q1/6886 , C12Q2600/112 , C12Q2600/158 , C12Q2600/178 , G06F19/18 , G06F19/20
Abstract: The present invention provides a method for classification of thyroid tumors through the analysis of the expression patterns of specific microRNAs in fine needle aspiration samples. Thyroid tumor classification according to a microRNA expression signature allows optimization of diagnosis and treatment, as well as determination of signature-specific therapy.
Abstract translation: 本发明提供了通过分析细针抽吸样品中特异性微小RNA的表达模式来分类甲状腺肿瘤的方法。 根据微小RNA表达特征的甲状腺肿瘤分类可以优化诊断和治疗，以及确定特异性特异性治疗。
-
8.发明申请COMPOSITIONS AND METHODS FOR DETERMINING THE PROGNOSIS OF BLADDER UROTHELIAL CANCER 审中-公开用于确定乳腺癌的预后的组合物和方法公开(公告)号：US20160186271A1
公开(公告)日：2016-06-30
申请号：US14976978
申请日：2015-12-21
Applicant: ROSETTA GENOMICS LTD.
Inventor： Ofer Nativ , Yaron Goren
IPC: C12Q1/68
CPC classification number: C12Q1/6886 , C12Q2600/112 , C12Q2600/118 , C12Q2600/136 , C12Q2600/158 , C12Q2600/178
Abstract: Described herein are compositions and methods for the prediction of bladder cancer risk of invasiveness. The compositions are microRNA molecules associated with the prognosis of bladder cancer, as well as various nucleic acid molecules relating thereto or derived therefrom.
Abstract translation: 本文描述了预测膀胱癌侵袭风险的组合物和方法。 所述组合物是与膀胱癌预后相关的微小RNA分子，以及与之相关的或从其衍生的各种核酸分子。
-
公开(公告)号：US20160046941A1
公开(公告)日：2016-02-18
申请号：US14833889
申请日：2015-08-24
Applicant: Regulus Therapeutics Inc. , Rosetta Genomics Ltd.
Inventor： C. Frank Bennett , Ayelet Chajut , Christine Esau , Eric Marcusson , Noga Yerushalmi
IPC: C12N15/113 , A61K45/06 , A61K31/7088
CPC classification number: C12N15/113 , A61K31/407 , A61K31/44 , A61K31/4745 , A61K31/513 , A61K31/555 , A61K31/704 , A61K31/7048 , A61K31/7068 , A61K31/7088 , A61K31/7105 , A61K45/06 , C12N2310/113 , C12N2310/141 , C12N2310/315 , C12N2310/321 , C12N2310/3341 , C12N2310/346 , C12N2310/3525
Abstract: Provided herein are methods for the treatment of liver cancer. These methods encompass the administration of a compound comprising a modified oligonucleotide, wherein the modified oligonucleotide is targeted to a miRNA. Also provided herein are compositions for the treatment of liver cancer. Such compositions include compounds comprising a modified oligonucleotide, wherein the modified oligonucleotide is targeted to a miRNA. Certain miRNAs have been identified as overexpressed in liver cancer, such as, for example, hepatocellular carcinoma, and are thus selected for targeting by modified oligonucleotides. Further, certain miRNAs have been identified as overexpressed in hepatocellular carcinoma cells exposed to dioxin, and are thus selected for targeting by modified oligonucleotides. Antisense inhibition of certain of these miRNAs has been found to inhibit cell proliferation and induce apoptosis.
Abstract translation: 本文提供了用于治疗肝癌的方法。 这些方法包括施用包含修饰的寡核苷酸的化合物，其中修饰的寡核苷酸靶向于miRNA。 本文还提供了用于治疗肝癌的组合物。 这样的组合物包括包含修饰的寡核苷酸的化合物，其中修饰的寡核苷酸靶向于miRNA。 某些miRNA已被鉴定为在肝癌中过度表达，例如肝细胞癌，因此被选择用修饰的寡核苷酸靶向。 此外，某些miRNA已被鉴定为在暴露于二恶英的肝细胞癌细胞中过表达，因此被选择用修饰的寡核苷酸靶向。 已经发现某些这些miRNA的反义抑制抑制细胞增殖并诱导细胞凋亡。
-
公开(公告)号：US09150857B2
公开(公告)日：2015-10-06
申请号：US14168812
申请日：2014-01-30
Applicant: Regulus Therapeutics Inc. , Rosetta Genomics Ltd.
Inventor： C. Frank Bennett , Ayelet Chajut , Christine Esau , Eric Marcusson , Noga Yerushalmi
IPC: C12N15/11 , C12N15/113 , A61K31/7105
CPC classification number: C12N15/113 , A61K31/407 , A61K31/44 , A61K31/4745 , A61K31/513 , A61K31/555 , A61K31/704 , A61K31/7048 , A61K31/7068 , A61K31/7088 , A61K31/7105 , A61K45/06 , C12N2310/113 , C12N2310/141 , C12N2310/315 , C12N2310/321 , C12N2310/3341 , C12N2310/346 , C12N2310/3525
Abstract: Provided herein are methods for the treatment of liver cancer. These methods encompass the administration of a compound comprising a modified oligonucleotide, wherein the modified oligonucleotide is targeted to a miRNA. Also provided herein are compositions for the treatment of liver cancer. Such compositions include compounds comprising a modified oligonucleotide, wherein the modified oligonucleotide is targeted to a miRNA. Certain miRNAs have been identified as overexpressed in liver cancer, such as, for example, hepatocellular carcinoma, and are thus selected for targeting by modified oligonucleotides. Further, certain miRNAs have been identified as overexpressed in hepatocellular carcinoma cells exposed to dioxin, and are thus selected for targeting by modified oligonucleotides. Antisense inhibition of certain of these miRNAs has been found to inhibit cell proliferation and induce apoptosis.
Abstract translation: 本文提供了用于治疗肝癌的方法。 这些方法包括施用包含修饰的寡核苷酸的化合物，其中修饰的寡核苷酸靶向于miRNA。 本文还提供了用于治疗肝癌的组合物。 这样的组合物包括包含修饰的寡核苷酸的化合物，其中修饰的寡核苷酸靶向于miRNA。 某些miRNA已被鉴定为在肝癌中过度表达，例如肝细胞癌，因此被选择用修饰的寡核苷酸靶向。 此外，某些miRNA已被鉴定为在暴露于二恶英的肝细胞癌细胞中过表达，因此被选择用修饰的寡核苷酸靶向。 已经发现某些这些miRNA的反义抑制抑制细胞增殖并诱导细胞凋亡。
-
-
-
-
-
-
-
-
-
Search Results
58
records
(took 0.043 seconds)
